Adial Pharmaceuticals, Inc. (ADIL) 10-Year Financial Performance & Capital Metrics

ADIL • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Show more

Revenue $0
EBITDA -$8M -20.3%
Net Income -$13M -88.5%
EPS (Diluted) -0.71 +86.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -323.8% -70.2%
ROIC -789.49% +43.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM38.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.53%

ROCE

10Y Avg-408.65%

5Y Avg-250.04%

3Y Avg-206.74%

Latest-203.25%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	565	565	565	563	565	564	0	0	564	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-565	-565	-565	-563	-565	-564	0	0	-564	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	0%	0%	-0%	0%	1%	-	-	1%
Operating Expenses+	819.26K	410.81K	995.29K	6.99M	8.24M	10.93M	19.29M	10.86M	6.89M	8.28M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	497.15K	264.66K	813.18K	6.62M	4.28M	5.07M	9.34M	8.91M	5.62M	5.06M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	322.11K	146.14K	182.11K	368.46K	3.97M	5.85M	8.4M	1.95M	1.27M	3.23M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	1.55M	0	-564	0
Operating Income+	-819.26K	-410.81K	-995.29K	-6.99M	-8.24M	-10.93M	-19.29M	-10.86M	-6.89M	-8.28M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.5%	-1.42%	-6.02%	-0.18%	-0.33%	-0.77%	0.44%	0.37%	-0.2%
EBITDA+	-818.69K	-410.24K	-994.72K	-6.99M	-8.24M	-10.93M	-19.23M	-10.86M	-6.89M	-8.28M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.5%	-1.42%	-6.02%	-0.18%	-0.33%	-0.76%	0.44%	0.37%	-0.2%
D&A (Non-Cash Add-back)	565	565	565	563	565	564	55.11K	564	564	565
EBIT	-817.99K	-410.56K	-994.92K	-10.46M	-8.59M	-10.89M	-17.74M	-10.86M	-7M	-8.28M
Net Interest Income+	0	-9.4K	-144.17K	-1.16M	95.23K	32.49K	6.54K	63.34K	69.78K	178.66K
Interest Income	1.26K	240	367	7.39K	95.23K	32.49K	6.54K	63.34K	69.78K	178.66K
Interest Expense	0	9.64K	144.54K	1.17M	0	0	0	0	0	0
Other Income/Expense	1.26K	-9.39K	-144.17K	-4.64M	-346.53K	34.99K	-228.68K	63.34K	-113.94K	-4.91M
Pretax Income+	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.89M	-19.52M	-10.8M	-7M	-13.2M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	1.26K	0	367	0	0	-32.49K	-94.08K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.18%	1%	1%
Net Income+	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.86M	-19.42M	-12.73M	-7M	-13.2M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.49%	-1.71%	-9.21%	0.26%	-0.26%	-0.79%	0.34%	0.45%	-0.88%
Net Income (Continuing)	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.86M	-19.42M	-10.8M	-7M	-13.2M
Discontinued Operations	0	0	0	0	0	0	0	-1.94M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.28	-2.20	-5.20	-61.10	-21.80	-21.79	-26.12	-11.98	-5.44	-0.71
EPS Growth %	-	0.49%	-1.36%	-10.75%	0.64%	0%	-0.2%	0.54%	0.55%	0.87%
EPS (Basic)	-4.28	-2.20	-5.20	-61.10	-21.80	-21.79	-26.12	-11.98	-5.44	-0.71
Diluted Shares Outstanding	191.28K	191.13K	218.99K	190.37K	394.1K	498.52K	743.55K	1.06M	1.42M	18.59M
Basic Shares Outstanding	191.28K	191.13K	218.99K	190.37K	394.1K	498.52K	743.55K	1.06M	1.42M	18.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	205.55K	141.41K	27.25K	4.69M	7.67M	5.14M	6.46M	4.78M	3.2M	4.06M
Cash & Short-Term Investments	162.38K	87.99K	18.25K	3.87M	6.78M	4.4M	6.06M	4M	2.83M	3.75M
Cash Only	162.38K	87.99K	18.25K	3.87M	6.78M	4.4M	6.06M	4M	2.83M	3.75M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	35.12K	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	43.17K	0	9K	317.55K	359.5K	501.69K	389.5K	349.44K	371.6K	308.24K
Total Non-Current Assets+	10.68K	10.11K	7.3K	6.74K	6.17K	355.61K	1.17M	952.87K	1.54M	985.18K
Property, Plant & Equipment	0	0	0	0	0	0	304.36K	244.42K	3.91K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	248.97K	0	0	0
Intangible Assets	8.43K	7.86K	7.3K	6.74K	6.17K	5.61K	5.04K	4.48K	3.91K	3.35K
Long-Term Investments	0	0	0	0	0	350K	0	0	1.53M	981.83K
Other Non-Current Assets	2.25K	2.25K	0	0	0	0	455K	703.97K	-3.91K	0
Total Assets+	216.22K	151.53K	34.55K	4.7M	7.68M	5.49M	7.63M	5.73M	4.74M	5.04M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.3%	-0.77%	135.03%	0.63%	-0.28%	0.39%	-0.25%	-0.17%	0.06%
Total Current Liabilities+	53.08K	255.02K	1.03M	257.97K	539.05K	1.51M	2.72M	1.79M	653.08K	975.86K
Accounts Payable	37.48K	20.01K	342.08K	99.67K	190.2K	648.74K	286.19K	276.41K	127.39K	250.13K
Days Payables Outstanding	24.22K	12.93K	220.99K	64.62K	122.88K	419.84K	-	-	82.44K	-
Short-Term Debt	0	234.25K	689.26K	0	0	0	49.59K	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	15.6K	752	752	132.34K	84.93K	534.2K	1.87M	1.08M	525.69K	405.25K
Current Ratio	3.87x	0.55x	0.03x	18.19x	14.24x	3.41x	2.37x	2.67x	4.90x	4.16x
Quick Ratio	3.87x	0.55x	0.03x	18.19x	14.24x	3.41x	2.37x	2.67x	4.90x	4.16x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	1.4M	665.44K	437	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	207.38K	150.55K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	182.31K	22.9K	437	0
Other Non-Current Liabilities	0	0	0	0	0	0	1.01M	492K	0	0
Total Liabilities	53.08K	255.02K	1.03M	257.97K	539.05K	1.51M	4.13M	2.46M	653.51K	975.86K
Total Debt+	0	234.25K	689.26K	0	0	0	256.96K	207.38K	0	0
Net Debt	-162.38K	146.26K	671.02K	-3.87M	-6.78M	-4.4M	-5.81M	-3.79M	-2.83M	-3.75M
Debt / Equity	-	-	-	-	-	-	0.07x	0.06x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-42.60x	-6.89x	-5.99x	-	-	-	-	-	-
Total Equity+	163.15K	-103.49K	-997.55K	4.44M	7.14M	3.99M	3.51M	3.28M	4.08M	4.07M
Equity Growth %	-	-1.63%	-8.64%	5.45%	0.61%	-0.44%	-0.12%	-0.07%	0.25%	-0%
Book Value per Share	0.85	-0.54	-4.56	23.33	18.12	8.00	4.72	3.08	2.87	0.22
Total Shareholders' Equity	163.15K	-103.49K	-997.55K	4.44M	7.14M	3.99M	3.51M	3.28M	4.08M	4.07M
Common Stock	9.68M	9.83M	3.27K	6.86K	10.37K	14.39K	20.95K	1.07K	1.66K	6.47K
Retained Earnings	-9.52M	-9.94M	-403.99K	-12.04M	-20.63M	-31.52M	-50.94M	-63.67M	-68.8M	-82M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-596.83K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-465.22K	-274.38K	-494.86K	-2.5M	-6.34M	-7.63M	-11.95M	-11.19M	-6.81M	-6.92M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.41%	-0.8%	-4.05%	-1.54%	-0.2%	-0.57%	0.06%	0.39%	-0.02%
Net Income	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.89M	-19.42M	-12.73M	-7M	-13.2M
Depreciation & Amortization	565	565	565	563	565	564	55.11K	60.5K	564	565
Stock-Based Compensation	250.82K	153.56K	205.4K	5.37M	1.6M	2.01M	4.24M	3.37M	1.75M	796.83K
Deferred Taxes	0	0	0	3.48M	0	-1.56M	-94.08K	-502	0	0
Other Non-Cash Items	1.09K	0	102.26K	1.13M	441.76K	1.56M	1.81M	-522K	-757.66K	5.09M
Working Capital Changes	100.29K	-8.32K	336.37K	-849.32K	208.17K	1.25M	1.46M	-1.37M	-794.21K	386.14K
Change in Receivables	0	-117	-367	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	15.84K	-17.47K	324.82K	-34.81K	90.53K	624.79K	-353.77K	108.35K	-159.41K	171.01K
Cash from Investing+	0	0	35.12K	0	0	-350K	-34.02K	0	1.5M	0
Capital Expenditures	0	0	0	0	0	0	-64.61K	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	35.12K	0	0	-350K	0	0	1.5M	0
Cash from Financing+	0	200K	390K	6.35M	9.25M	5.61M	13.64M	9.13M	4.13M	7.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	156.25K	1.05M	450.01K	1.89M	1.86K	0	3.82M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-465.22K	-274.38K	-494.86K	-2.5M	-6.34M	-7.63M	-12.01M	-11.19M	0	-6.92M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.41%	-0.8%	-4.05%	-1.54%	-0.2%	-0.57%	0.07%	1%	-
FCF per Share	-2.43	-1.44	-2.26	-13.12	-16.08	-15.31	-16.16	-10.52	-	-0.37
FCF Conversion (FCF/Net Income)	0.57x	0.65x	0.43x	0.21x	0.74x	0.70x	0.62x	0.88x	0.97x	0.52x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-501.39%	-1408.84%	-	-675.5%	-148.36%	-195.22%	-518.38%	-375.32%	-190.27%	-323.8%
Return on Invested Capital (ROIC)	-80005.57%	-1415.37%	-	-4265.15%	-1321.58%	-	-	-	-1399%	-789.49%
Debt / Equity	-	-	-	-	-	-	0.07x	0.06x	-	-
Interest Coverage	-	-42.60x	-6.89x	-5.99x	-	-	-	-	-	-
FCF Conversion	0.57x	0.65x	0.43x	0.21x	0.74x	0.70x	0.62x	0.88x	0.97x	0.52x

Frequently Asked Questions

Growth & Financials

Adial Pharmaceuticals, Inc. (ADIL) grew revenue by 0.0% over the past year. Growth has been modest.

Adial Pharmaceuticals, Inc. (ADIL) reported a net loss of $8.1M for fiscal year 2024.

Dividend & Returns

Adial Pharmaceuticals, Inc. (ADIL) has a return on equity (ROE) of -323.8%. Negative ROE indicates the company is unprofitable.

Adial Pharmaceuticals, Inc. (ADIL) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Adial Pharmaceuticals, Inc. (ADIL) 10-Year Financial Performance & Capital Metrics

ADIL • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$8M -20.3%
Net Income -$13M -88.5%
EPS (Diluted) -0.71 +86.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -323.8% -70.2%
ROIC -789.49% +43.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM38.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.53%

ROCE

10Y Avg-408.65%

5Y Avg-250.04%

3Y Avg-206.74%

Latest-203.25%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	565	565	565	563	565	564	0	0	564	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-565	-565	-565	-563	-565	-564	0	0	-564	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	0%	0%	-0%	0%	1%	-	-	1%
Operating Expenses+	819.26K	410.81K	995.29K	6.99M	8.24M	10.93M	19.29M	10.86M	6.89M	8.28M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	497.15K	264.66K	813.18K	6.62M	4.28M	5.07M	9.34M	8.91M	5.62M	5.06M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	322.11K	146.14K	182.11K	368.46K	3.97M	5.85M	8.4M	1.95M	1.27M	3.23M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	1.55M	0	-564	0
Operating Income+	-819.26K	-410.81K	-995.29K	-6.99M	-8.24M	-10.93M	-19.29M	-10.86M	-6.89M	-8.28M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.5%	-1.42%	-6.02%	-0.18%	-0.33%	-0.77%	0.44%	0.37%	-0.2%
EBITDA+	-818.69K	-410.24K	-994.72K	-6.99M	-8.24M	-10.93M	-19.23M	-10.86M	-6.89M	-8.28M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.5%	-1.42%	-6.02%	-0.18%	-0.33%	-0.76%	0.44%	0.37%	-0.2%
D&A (Non-Cash Add-back)	565	565	565	563	565	564	55.11K	564	564	565
EBIT	-817.99K	-410.56K	-994.92K	-10.46M	-8.59M	-10.89M	-17.74M	-10.86M	-7M	-8.28M
Net Interest Income+	0	-9.4K	-144.17K	-1.16M	95.23K	32.49K	6.54K	63.34K	69.78K	178.66K
Interest Income	1.26K	240	367	7.39K	95.23K	32.49K	6.54K	63.34K	69.78K	178.66K
Interest Expense	0	9.64K	144.54K	1.17M	0	0	0	0	0	0
Other Income/Expense	1.26K	-9.39K	-144.17K	-4.64M	-346.53K	34.99K	-228.68K	63.34K	-113.94K	-4.91M
Pretax Income+	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.89M	-19.52M	-10.8M	-7M	-13.2M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	1.26K	0	367	0	0	-32.49K	-94.08K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.18%	1%	1%
Net Income+	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.86M	-19.42M	-12.73M	-7M	-13.2M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.49%	-1.71%	-9.21%	0.26%	-0.26%	-0.79%	0.34%	0.45%	-0.88%
Net Income (Continuing)	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.86M	-19.42M	-10.8M	-7M	-13.2M
Discontinued Operations	0	0	0	0	0	0	0	-1.94M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.28	-2.20	-5.20	-61.10	-21.80	-21.79	-26.12	-11.98	-5.44	-0.71
EPS Growth %	-	0.49%	-1.36%	-10.75%	0.64%	0%	-0.2%	0.54%	0.55%	0.87%
EPS (Basic)	-4.28	-2.20	-5.20	-61.10	-21.80	-21.79	-26.12	-11.98	-5.44	-0.71
Diluted Shares Outstanding	191.28K	191.13K	218.99K	190.37K	394.1K	498.52K	743.55K	1.06M	1.42M	18.59M
Basic Shares Outstanding	191.28K	191.13K	218.99K	190.37K	394.1K	498.52K	743.55K	1.06M	1.42M	18.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	205.55K	141.41K	27.25K	4.69M	7.67M	5.14M	6.46M	4.78M	3.2M	4.06M
Cash & Short-Term Investments	162.38K	87.99K	18.25K	3.87M	6.78M	4.4M	6.06M	4M	2.83M	3.75M
Cash Only	162.38K	87.99K	18.25K	3.87M	6.78M	4.4M	6.06M	4M	2.83M	3.75M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	35.12K	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	43.17K	0	9K	317.55K	359.5K	501.69K	389.5K	349.44K	371.6K	308.24K
Total Non-Current Assets+	10.68K	10.11K	7.3K	6.74K	6.17K	355.61K	1.17M	952.87K	1.54M	985.18K
Property, Plant & Equipment	0	0	0	0	0	0	304.36K	244.42K	3.91K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	248.97K	0	0	0
Intangible Assets	8.43K	7.86K	7.3K	6.74K	6.17K	5.61K	5.04K	4.48K	3.91K	3.35K
Long-Term Investments	0	0	0	0	0	350K	0	0	1.53M	981.83K
Other Non-Current Assets	2.25K	2.25K	0	0	0	0	455K	703.97K	-3.91K	0
Total Assets+	216.22K	151.53K	34.55K	4.7M	7.68M	5.49M	7.63M	5.73M	4.74M	5.04M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.3%	-0.77%	135.03%	0.63%	-0.28%	0.39%	-0.25%	-0.17%	0.06%
Total Current Liabilities+	53.08K	255.02K	1.03M	257.97K	539.05K	1.51M	2.72M	1.79M	653.08K	975.86K
Accounts Payable	37.48K	20.01K	342.08K	99.67K	190.2K	648.74K	286.19K	276.41K	127.39K	250.13K
Days Payables Outstanding	24.22K	12.93K	220.99K	64.62K	122.88K	419.84K	-	-	82.44K	-
Short-Term Debt	0	234.25K	689.26K	0	0	0	49.59K	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	15.6K	752	752	132.34K	84.93K	534.2K	1.87M	1.08M	525.69K	405.25K
Current Ratio	3.87x	0.55x	0.03x	18.19x	14.24x	3.41x	2.37x	2.67x	4.90x	4.16x
Quick Ratio	3.87x	0.55x	0.03x	18.19x	14.24x	3.41x	2.37x	2.67x	4.90x	4.16x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	1.4M	665.44K	437	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	207.38K	150.55K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	182.31K	22.9K	437	0
Other Non-Current Liabilities	0	0	0	0	0	0	1.01M	492K	0	0
Total Liabilities	53.08K	255.02K	1.03M	257.97K	539.05K	1.51M	4.13M	2.46M	653.51K	975.86K
Total Debt+	0	234.25K	689.26K	0	0	0	256.96K	207.38K	0	0
Net Debt	-162.38K	146.26K	671.02K	-3.87M	-6.78M	-4.4M	-5.81M	-3.79M	-2.83M	-3.75M
Debt / Equity	-	-	-	-	-	-	0.07x	0.06x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-42.60x	-6.89x	-5.99x	-	-	-	-	-	-
Total Equity+	163.15K	-103.49K	-997.55K	4.44M	7.14M	3.99M	3.51M	3.28M	4.08M	4.07M
Equity Growth %	-	-1.63%	-8.64%	5.45%	0.61%	-0.44%	-0.12%	-0.07%	0.25%	-0%
Book Value per Share	0.85	-0.54	-4.56	23.33	18.12	8.00	4.72	3.08	2.87	0.22
Total Shareholders' Equity	163.15K	-103.49K	-997.55K	4.44M	7.14M	3.99M	3.51M	3.28M	4.08M	4.07M
Common Stock	9.68M	9.83M	3.27K	6.86K	10.37K	14.39K	20.95K	1.07K	1.66K	6.47K
Retained Earnings	-9.52M	-9.94M	-403.99K	-12.04M	-20.63M	-31.52M	-50.94M	-63.67M	-68.8M	-82M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-596.83K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-465.22K	-274.38K	-494.86K	-2.5M	-6.34M	-7.63M	-11.95M	-11.19M	-6.81M	-6.92M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.41%	-0.8%	-4.05%	-1.54%	-0.2%	-0.57%	0.06%	0.39%	-0.02%
Net Income	-817.99K	-420.2K	-1.14M	-11.63M	-8.59M	-10.89M	-19.42M	-12.73M	-7M	-13.2M
Depreciation & Amortization	565	565	565	563	565	564	55.11K	60.5K	564	565
Stock-Based Compensation	250.82K	153.56K	205.4K	5.37M	1.6M	2.01M	4.24M	3.37M	1.75M	796.83K
Deferred Taxes	0	0	0	3.48M	0	-1.56M	-94.08K	-502	0	0
Other Non-Cash Items	1.09K	0	102.26K	1.13M	441.76K	1.56M	1.81M	-522K	-757.66K	5.09M
Working Capital Changes	100.29K	-8.32K	336.37K	-849.32K	208.17K	1.25M	1.46M	-1.37M	-794.21K	386.14K
Change in Receivables	0	-117	-367	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	15.84K	-17.47K	324.82K	-34.81K	90.53K	624.79K	-353.77K	108.35K	-159.41K	171.01K
Cash from Investing+	0	0	35.12K	0	0	-350K	-34.02K	0	1.5M	0
Capital Expenditures	0	0	0	0	0	0	-64.61K	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	35.12K	0	0	-350K	0	0	1.5M	0
Cash from Financing+	0	200K	390K	6.35M	9.25M	5.61M	13.64M	9.13M	4.13M	7.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	156.25K	1.05M	450.01K	1.89M	1.86K	0	3.82M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-465.22K	-274.38K	-494.86K	-2.5M	-6.34M	-7.63M	-12.01M	-11.19M	0	-6.92M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.41%	-0.8%	-4.05%	-1.54%	-0.2%	-0.57%	0.07%	1%	-
FCF per Share	-2.43	-1.44	-2.26	-13.12	-16.08	-15.31	-16.16	-10.52	-	-0.37
FCF Conversion (FCF/Net Income)	0.57x	0.65x	0.43x	0.21x	0.74x	0.70x	0.62x	0.88x	0.97x	0.52x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-501.39%	-1408.84%	-	-675.5%	-148.36%	-195.22%	-518.38%	-375.32%	-190.27%	-323.8%
Return on Invested Capital (ROIC)	-80005.57%	-1415.37%	-	-4265.15%	-1321.58%	-	-	-	-1399%	-789.49%
Debt / Equity	-	-	-	-	-	-	0.07x	0.06x	-	-
Interest Coverage	-	-42.60x	-6.89x	-5.99x	-	-	-	-	-	-
FCF Conversion	0.57x	0.65x	0.43x	0.21x	0.74x	0.70x	0.62x	0.88x	0.97x	0.52x

Frequently Asked Questions

Growth & Financials

Adial Pharmaceuticals, Inc. (ADIL) grew revenue by 0.0% over the past year. Growth has been modest.

Adial Pharmaceuticals, Inc. (ADIL) reported a net loss of $8.1M for fiscal year 2024.

Dividend & Returns

Adial Pharmaceuticals, Inc. (ADIL) has a return on equity (ROE) of -323.8%. Negative ROE indicates the company is unprofitable.

Adial Pharmaceuticals, Inc. (ADIL) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.